• Briacell Therapeutics Corp BCT.TO reported a quarterly adjusted loss of 22 cents​​ per share for the quarter ended October 31, lower than the same quarter last year, when the company reported EPS of 37 cents. The lone analyst forecast for the quarter was for a loss of 8 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Briacell Therapeutics Corp's reported EPS for the quarter was a loss of 22 cents​.

• The company reported a quarterly loss of $5.8 million.

• Briacell Therapeutics Corp shares had fallen by 51.0% this quarter and lost 89.6% so far this year.

FORECAST CHANGES

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Briacell Therapeutics Corp is $15.00

This summary was machine generated from LSEG data December 17 at 03:20 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)